[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656673":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":26,"interventions":40,"overallOfficials":17,"centralContacts":54,"locations":60,"responsibleParty":79,"collaborators":17,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":17,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":17,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":63,"whyStopped":17,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"ESS","Epistaxis Severity Score","1,3.6.12 months after surgery",{"measure":14,"description":15,"timeFrame":16},"Hb","Hemoglobin (Hb)","1,3,6,12months after surgery",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"SINGLE",[25],"OUTCOMES_ASSESSOR",[27,34],{"label":28,"type":29,"description":30,"interventionNames":31},"Experiment","EXPERIMENTAL","surgery combined with intravenous injection of bevacizumab",[32,33],"Drug: Bevacizumab","Procedure: nasal electrocoagulation.",{"label":35,"type":36,"description":37,"interventionNames":38},"Active comparator","ACTIVE_COMPARATOR","Surgery combined with oral thalidomide",[33,39],"Drug: Thalidomide (50mg)",[41,46,50],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":17},"DRUG","Bevacizumab","Bevacizumab is administered intravenously at 5 mg\u002Fkg body weight, 1 to 2 times annually, starting one month after nasal electrocoagulation.",[28],{"type":47,"name":48,"description":48,"armGroupLabels":49,"otherNames":17},"PROCEDURE","nasal electrocoagulation.",[35,28],{"type":42,"name":51,"description":52,"armGroupLabels":53,"otherNames":17},"Thalidomide (50mg)","Oral thalidomide is initiated at 50 mg twice daily (100 mg per day) one month after nasal electrocoagulation.",[35],[55],{"name":56,"role":57,"phone":58,"phoneExt":17,"email":59},"Hong-gang Duan, doctor","CONTACT","13429124832","2314061@zju.edu.cn",[61],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"The Second Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310009","China","CN",{"type":70,"coordinates":71},"Point",[72,73],120.16142,30.29365,{"lat":73,"lon":72},[76,77],{"name":56,"role":57,"phone":58,"phoneExt":17,"email":59},{"name":78,"role":57,"phone":17,"phoneExt":17,"email":59},"Hong-gang 段",{"type":80,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100656673","phase-2-bevacizumab-in-the-treatment-of-hht-100656673",false,"NCT07828015","Bevacizumab in the Treatment of HHT","Observation on the Efficacy of Bevacizumab in the Treatment of Hereditary Haemorrhagic Telangiectasia","Inclusion Criteria:\n\n* Definite HHT diagnosis is established by either clinical assessment according to the Curaçao criteria or genetic confirmation.\n\nClinical diagnosis (Curaçao criteria)\n\nPatients who meet at least 3 of the following 4 items are diagnosed with definite HHT:\n\nSpontaneous, recurrent epistaxis Multiple mucocutaneous telangiectasias at typical sites Visceral arteriovenous malformations (lung, liver, brain, gastrointestinal tract, etc.) Positive family history of HHT in a first-degree relative Genetic diagnosis Identification of a pathogenic germline mutation in HHT-associated genes (ENG, ACVRL1) confirms the diagnosis of HHT.\n\nExclusion Criteria:\n\n* Minors, patients with mild epistaxis that can be well controlled by other treatments, and patients with any contraindication to bevacizumab treatment.","ALL","18 Years","75 Years",{"count":92,"type":93},40,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","Clinical Study Abstract (Ethics Application) Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by recurrent intractable epistaxis and multi-organ arteriovenous malformations. Moderate-to-severe patients often develop refractory anemia with severely impaired quality of life. Current stepwise therapeutic strategies have substantial limitations, including frequent adverse reactions of thalidomide, high recurrence rates after electrocoagulation, and severe surgical trauma, resulting in a lack of safe and individualized treatment options. Our preliminary clinical practice has verified the promising efficacy and long-term benefits of bevacizumab in severe HHT-related epistaxis. However, obvious interindividual variability and occasional adverse events exist, and the underlying mechanism remains unclear. This study aims to systematically evaluate the efficacy and safety of bevacizumab for severe HHT-associated epistaxis, explore the influences of baseline clinical and genetic factors on prognosis, and investigate the mechanism of treatment heterogeneity, so as to optimize individualized therapeutic strategies and provide clinical evidence for precise management of HHT in China.",[99,100],"Bevacizimab","HHT",[100,102],"bevacizimab","2026-09-14",{"date":105,"type":106},"2026-09-18","ACTUAL",{"date":108,"type":106},"2025-05-01",{"date":110,"type":93},"2029-09-01",{"name":5,"class":6},1]